Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Eli Lilly Signs Development Deal for Novel Immunology Drug

By Ryan Bushey | July 24, 2017

Eli Lilly is bolstering its autoimmune offerings with a new co-development and commercialization agreement.

The deal will focus on a promising drug called NKTR-358, developed by Nektar Therapeutics. It’s being designed to target the interleukin (IL-2) receptor complex in the body in an effort to stimulate the proliferation of regulatory T-cells. Activating these cells could bring the immune system back into balance.

As part of this agreement, Nektar will receive an initial payment of $150 million from Eli Lilly with the potential to receive an estimated $250 million if the drug achieves certain development and regulatory milestones, according to the announcement.

Investigators achieved the first human dose of NKTR-358 as part of a Phase I clinical trial in March 2017 with the goal of measuring observed changes and functional activity of regulatory T cells in approximately 50 healthy patients.

Both companies will co-develop NKTR-358 with Nektar being responsible for completing Phase 1 clinical development, but then the costs will shift for Phase 2 in which Lilly will handle 75 percent and Nektar the remaining 25 percent. 

Furthermore, Nektar will be able to receive double-digit royalties that increase based on its Phase III investment and product sales with Lilly handling all costs of global commercialization.

“We are very pleased to enter into this collaboration with Lilly as they have strong expertise in immunology and a successful track record in bringing novel therapies to market,” said Nektar’s President and CEO Howard W. Robin, in a statement. Importantly, this agreement enables the broad development of NKTR-358 in multiple autoimmune conditions in order to achieve its full potential as a first-in-class resolution therapeutic.”

Proving this drug’s mechanism of action is viable could ultimately yield a multi-purpose therapy that could work for autoimmune conditions like lupus and psoriasis. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE